Company case study
GLP-1 drugs (e.g., Ozempic)
GLP-1 drugs (e.g., Ozempic): GLP-1 drugs are medications used to treat type 2 diabetes and obesity, known for their weight loss effects. It came up on My First Million, hosted by Sam Parr and Shaan Puri, in the episode "Mohnish Pabrai: How to be a top 1% investor" (aired May 22, 2026).
At a glance
| Podcast | My First Million |
|---|---|
| Hosted by | Sam Parr and Shaan Puri |
| Episode | Mohnish Pabrai: How to be a top 1% investor |
| Aired | May 22, 2026 |
| Revenue and traction | Currently generating double the revenue of AI companies, with an estimated $79 billion a year versus $40 billion. |
| Category | E-commerce |
Figures and claims are as told on the episode, summarized from the transcript. Check the date: they describe the company at the time it aired.
What the episode said
Mohnish Pabrai: How to be a top 1% investor · aired May 22, 2026 · hosted by Sam Parr and Shaan Puri
Why it works
These drugs have gained popularity due to their effectiveness and are generating significant revenue, surpassing many sectors including AI.
The playbook
The success of GLP-1 drugs is attributed to their innovative approach to treating diabetes and obesity, along with ongoing improvements in medical science.
Also mentioned
The conversation indicates that the market for these drugs will continue to grow as science advances.
Why this works now (our analysis)
FDA approval of semaglutide for weight management has driven demand for GLP-1 drugs, making them a viable option for treating obesity and type 2 diabetes. A targeted advertising campaign on platforms like Facebook and Instagram has allowed companies to reach consumers effectively, generating substantial revenue. A significant risk includes the high customer acquisition cost (CAC) associated with promoting these medications, which may lead to longer payback windows and impact profitability if not managed carefully.